Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.
MaesTTRo (Transthyretin [ATTR] Amyloidosis) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about ATTR and its different variants and how they can can be better diagnosed, managed, and treated.
What is the Condition Being Studied?
Amyloid Transthyretin Amyloidosis (ATTR)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with ATTR
- Do not have primary or light chain amyloidosis
- Are not enrolled in an interventional clinical trial
For more information, contact the study team at samira.dixon@duke.edu.
Age Group
Adults
What is Involved?
If you want to participate in the study, it will not involve any type of experimental drug or other intervention. We will ask you to fill out surveys about your health about every 6 months at your routine clinic appointments. We will collect this information from you for up to 7 years.
Study Details
Full Title
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
Principal Investigator
Cardiologist
Protocol Number
IRB:
PRO00115927
Phase
Phase
N/A
Enrollment Status
Open for Enrollment Soon